Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives.

Joshua F BakerCharles E LeonardVincent Lo ReMichael H WeismanMichael D George Jonathan Kay

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2020)

The uptake of infliximab biosimilars has been slow at an academic medical center compared to a nearby VAMC, where financial savings are realized by the institution from its use. Slow adoption of biosimilar medications may impact the rates of decline in costs.

Keyphrases

healthcare
public health
mental health
electronic health record
health information
ulcerative colitis
young adults
risk assessment
hepatitis c virus
hiv infected